Wall Street analysts expect that Novo Nordisk A/S (NYSE:NVO) will report $0.56 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Novo Nordisk A/S’s earnings. The highest EPS estimate is $0.60 and the lowest is $0.54. Novo Nordisk A/S reported earnings per share of $0.60 in the same quarter last year, which suggests a negative year-over-year growth rate of 6.7%. The company is scheduled to announce its next earnings results before the market opens on Wednesday, August 9th.
On average, analysts expect that Novo Nordisk A/S will report full year earnings of $2.31 per share for the current fiscal year, with EPS estimates ranging from $2.29 to $2.34. For the next year, analysts forecast that the firm will report earnings of $2.46 per share, with EPS estimates ranging from $2.34 to $2.52. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Novo Nordisk A/S.
NVO has been the subject of a number of research reports. TheStreet raised shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Wednesday, June 21st. BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th. Finally, HSBC Holdings plc cut shares of Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $53.00.
Institutional investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC boosted its position in Novo Nordisk A/S by 155.6% in the first quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the last quarter. Perigon Wealth Management LLC purchased a new position in Novo Nordisk A/S during the fourth quarter worth $105,000. Tower Research Capital LLC TRC boosted its position in Novo Nordisk A/S by 167.8% in the first quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the last quarter. Parallel Advisors LLC boosted its position in Novo Nordisk A/S by 120.3% in the first quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new position in Novo Nordisk A/S during the first quarter worth $127,000. 6.34% of the stock is owned by institutional investors.
Shares of Novo Nordisk A/S (NYSE NVO) traded down 1.38% during mid-day trading on Thursday, hitting $42.95. The stock had a trading volume of 1,233,659 shares. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $57.41. The company’s 50 day moving average price is $43.10 and its 200 day moving average price is $38.08. The stock has a market cap of $107.19 billion, a P/E ratio of 18.18 and a beta of 0.63.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
